HC Wainwright reissued their neutral rating on shares of Assembly Biosciences (NASDAQ:ASMB - Free Report) in a research report report published on Monday morning,Benzinga reports. HC Wainwright also issued estimates for Assembly Biosciences' Q1 2025 earnings at ($1.54) EPS, Q2 2025 earnings at ($1.54) EPS, Q3 2025 earnings at ($1.64) EPS, Q4 2025 earnings at ($1.57) EPS, FY2025 earnings at ($6.29) EPS, FY2026 earnings at ($9.05) EPS, FY2027 earnings at ($12.07) EPS, FY2028 earnings at ($12.32) EPS and FY2029 earnings at ($12.58) EPS.
Assembly Biosciences Trading Down 2.6 %
Shares of Assembly Biosciences stock traded down $0.28 on Monday, reaching $10.62. The stock had a trading volume of 12,009 shares, compared to its average volume of 24,885. The business's 50 day moving average is $12.55 and its two-hundred day moving average is $14.95. The company has a market cap of $79.68 million, a P/E ratio of -1.58 and a beta of 0.62. Assembly Biosciences has a 1 year low of $10.27 and a 1 year high of $19.93.
Assembly Biosciences (NASDAQ:ASMB - Get Free Report) last posted its earnings results on Thursday, March 20th. The biopharmaceutical company reported ($1.57) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.75) by $0.18. The business had revenue of $7.36 million for the quarter, compared to analysts' expectations of $7.05 million. Assembly Biosciences had a negative net margin of 144.05% and a negative return on equity of 121.46%. On average, equities analysts anticipate that Assembly Biosciences will post -6.87 EPS for the current fiscal year.
Insider Buying and Selling at Assembly Biosciences
In related news, Director Michael Houghton purchased 3,202 shares of the firm's stock in a transaction dated Monday, December 30th. The shares were purchased at an average price of $15.61 per share, with a total value of $49,983.22. Following the acquisition, the director now directly owns 3,202 shares of the company's stock, valued at approximately $49,983.22. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 5.10% of the stock is currently owned by company insiders.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. lifted its stake in Assembly Biosciences by 5,137.3% during the third quarter. JPMorgan Chase & Co. now owns 3,509 shares of the biopharmaceutical company's stock worth $53,000 after purchasing an additional 3,442 shares during the last quarter. Palumbo Wealth Management LLC purchased a new position in shares of Assembly Biosciences during the 4th quarter valued at about $180,000. Marshall Wace LLP lifted its position in Assembly Biosciences by 16.5% in the 4th quarter. Marshall Wace LLP now owns 14,823 shares of the biopharmaceutical company's stock worth $234,000 after buying an additional 2,098 shares during the last quarter. FMR LLC boosted its stake in Assembly Biosciences by 29.7% in the third quarter. FMR LLC now owns 15,855 shares of the biopharmaceutical company's stock worth $240,000 after buying an additional 3,635 shares in the last quarter. Finally, Man Group plc bought a new position in Assembly Biosciences during the fourth quarter valued at approximately $309,000. 19.92% of the stock is currently owned by hedge funds and other institutional investors.
Assembly Biosciences Company Profile
(
Get Free Report)
Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.
Featured Stories
Before you consider Assembly Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Assembly Biosciences wasn't on the list.
While Assembly Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
